GASTROINTESTINAL EFFECTS ASSOCIATED WITH THE ADMINISTRATION OF TIRZEPATIDE
DOI:
https://doi.org/10.63330/aurumpub.036-007Keywords:
Tirzepatide, Gastrointestinal effects, Type 2 diabetes mellitus, Obesity, Dual GLP-1/GIP receptor inhibitor, Nausea, Vomiting, DiarrheaAbstract
Tirzepatide, a dual agonist of GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors, has demonstrated superior efficacy in glycemic control and weight loss. However, its administration is consistently associated with gastrointestinal adverse effects, which represent the main cause of treatment discontinuation. This article reviews the main gastrointestinal effects of tirzepatide, its pathophysiological mechanisms, incidence, risk factors, clinical impact, and implications for medical practice.
Downloads
References
1. KARRAR, H.R.; et al. Tirzepatide-Induced Gastrointestinal Manifestations: A Systematic Review and Meta-Analysis. PubMed, 2023. Disponível em: https://pubmed.ncbi.nlm.nih.gov/37908927/
2. PATEL, H.; et al. Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials. Diabetes, Obesity and Metabolism, 2024. Disponível em: https://pubmed.ncbi.nlm.nih.gov/37853960/
3. MISHRA, R.; et al. Adverse Events Related to Tirzepatide: A Dose- Dependent Analysis of Gastrointestinal Symptoms. Journal of the Endocrine Society, 2023. Disponível em: https://pubmed.ncbi.nlm.nih.gov/36789109/
4. TONG, K.; et al. Gastrointestinal Adverse Events of Tirzepatide in the Treatment of Type 2 Diabetes Mellitus: Meta-Analysis and Trial Sequential Analysis. Medicine (Baltimore), 2023. Disponível em: https://pubmed.ncbi.nlm.nih.gov/37904345/
5. FRÍAS, J.P.; et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. The New England Journal of Medicine, 2021 — relata eventos gastrointestinais (náusea, diarreia e vômito) entre os desfechos adversos mais frequentes. Disponível em: https://www.nejm.org/doi/full/10.1056/NEJMoa2107519
6. JASTREBOFF, A.M.; et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 2022 — descreve eventos gastrointestinais como os efeitos adversos mais relatados em estudos de obesidade. Disponível em: https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
7. TIAN, Q.; et al. Efficacy and Safety of Tirzepatide for Weight Loss: Focus on Gastrointestinal Side Effects. Frontiers in Endocrinology, 2025. Disponível em: https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2025. 1593134/full
8. ALMANSOUR, H.A.; et al. Real-World Safety Concerns of Tirzepatide: Gastrointestinal Adverse Events in Pharmacovigilance Data. Healthcare (Basel), 2025. Disponível em: https://www.mdpi.com/2227-9032/13/18/2259
9. Rubino, D.M.; et al. Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT-1 to -4 trials. Diabetes, Obesity and Metabolism, 2025. Disponível em: https://pubmed.ncbi.nlm.nih.gov/39789843/
10. FARZAM, K.; et al. Tirzepatide — Type 2 Diabetes and Weight Loss: Adverse Gastrointestinal Drug Reactions Profile. NCBI Bookshelf, 2024. Disponível em: https://www.ncbi.nlm.nih.gov/books/NBK585056/
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
